Primary glial and neuronal tumors of the ovary or peritoneum are rare neuroectodermal-type tumors similar to their counterparts in the central nervous system. We retrospectively reviewed 11 cases. These cases included 4 ependymomas, 6 astrocytic tumors, and 1 neurocytoma. Patients' age ranged from 9 to 50 years (mean, 26 y; median, 24 y). All ependymal tumors with detailed clinical history (n = 3) were not associated with any other ovarian neoplasm. In contrast, all astrocytic tumors were associated with immature teratoma (n = 4), mature cystic teratoma (n = 1), or mixed germ cell tumor (n = 1). The neurocytoma arose in association with mature teratomatous components in a patient with a history of treated mixed germ cell tumor. Immunohistochemical staining showed that 7 of 7 ependymal and astrocytic tumors (100%) were positive for glial fibrillary acidic protein, and 2 of 2 ependymomas (100%) were positive for both estrogen and progesterone receptors. The neurocytoma was positive for synaptophysin and negative for S100 protein, glial fibrillary acidic protein, and SALL4. No IDH1-R132H mutation was detected in 2 of 2 (0%) astrocytomas by immunohistochemistry. Next-generation sequencing was performed on additional 2 ependymomas and 2 astrocytomas but detected no mutations in a panel of 50 genes that included IDH1, IDH2, TP53, PIK3CA, EGFR, BRAF, and PTEN. Follow-up information was available for 8 patients, with the follow-up period ranging from 4 to 59 months (mean, 15 mo; median, 8.5 mo), of which 3 had no evidence of disease and 5 were alive with disease. In conclusion, primary glial and neuronal tumors of the ovary can arise independently or in association with other ovarian germ cell tumor components. Pathologists should be aware of these rare tumors and differentiate them from other ovarian neoplasms. Even though an IDH1 or IDH2 mutation is found in the majority of WHO grade II and III astrocytomas, and in secondary glioblastomas arising from them, such mutations were not identified in our series, suggesting that these tumors are molecularly different from their central nervous system counterparts despite their morphologic and immunophenotypic similarities.
P rimary glial and neuronal tumors of the ovary and/or peritoneum are rare neuroectodermal-type tumors, morphologically similar to their counterparts in the central nervous system (CNS). 1 Neuroectodermal-type tumors of the ovary are divided into 3 groups: differentiated tumors, primitive tumors, and anaplastic tumors, with the latter 2 groups being associated with poorer prognosis. 2 Despite the rapid advance in our understanding of CNS glial and neuronal tumors, as reflected by the introduction of integrated, molecular signature-based definitions of many pediatric and adult entities in the forthcoming World Health Organization (WHO) 2016 Classification of Tumours of Central Nervous System, 3 the corresponding tumors arising in extra-CNS locations have not been well studied.
The pathogenesis of glial and neuronal tumors of the gynecologic tract is largely poorly understood. They are considered to belong to the general category of teratomas 1 ; however, some tumors have been reported in association with epithelial ovarian tumors, adenosarcoma, or malignant mixed Mu¨llerian tumors. [4] [5] [6] [7] [8] [9] Clinical experience in the diagnosis and treatment of these neuroectodermal-type tumors of the ovary or peritoneum is limited.
In this study, we retrospectively reviewed 11 cases of primary glial or neuronal tumors of ovary/peritoneum, including 4 ependymomas, 6 astrocytic tumors, and 1 neurocytoma, and correlated the clinical, pathologic, and molecular characteristics with their counterparts in the CNS.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board. We searched the database of the Department of Pathology at The University of Texas MD Anderson Cancer Center between 1988 and 2015 and identified 11 primary glial or neuronal tumors of the ovary/peritoneum. Metastatic tumors were excluded from the study. Clinical data, including demographic information, diagnosis, and follow-up, were obtained from the medical records. Archived hematoxylin and eosin and immunohistochemistry (IHC) slides were retrieved and reviewed.
The following IHC stains were performed at outside institutions and were reviewed at our institution: CD57, CD99, desmin, epithelial membrane antigen (EMA), glial fibrillary acidic protein (GFAP), pancytokeratin, S100 protein, and synaptophysin. IHC stains performed at our institution included: calretinin (clone DC8, 1:120; Invitrogen, Carlsbad, CA), CD99 (clone 12E7, 1:300; Dako, Burlington, ON, Canada), EMA (clone GP1.4, 1:600; Novocastra, Leica Microsystems, Wetzlar, Germany), estrogen receptor (ER) (clone 6F11, diluted 1:35; Leica Microsystems), GFAP (1:7000; BD Biosciences, Franklin Lakes, NJ), inhibin (clone R1, 1:50; AbD Serotec, Oxford, UK), isocitrate dehydrogenase (IDH1-R132H) (clone H09, diluted 1:40; Dianova, Hamburg, Germany), keratin cocktail (AE1/AE3, 1:50, Dako; Cam5.2, 1:50, BD Biosciences; MNF116, 1:50, Dako; keratin 8 and 18, 1:25, Invitrogen), Ki-67 (clone MIB-1, 1:100; Dako), neurofilament (clone SEN28, 1:100; Invitrogen), neuronal nuclear antigen (Neu-N) (clone A60, 1:50; Bio SB, Santa Barbara, CA), phosphohistone H3 (pHH3) (1:400; Millipore, Billerica, MA), progesterone receptor (PR) (clone PgR1294, 1:200; Dako), S100 (clone 15E2E2, 1:900; Bi-oGenex, Fremont, CA), Spalt-like transcription factor 4 (SALL4) (clone 6E3, 1:100; Biocare, Concord, CA), and synaptophysin (clone 27G12, 1:600; Novocastra, Leica Microsystems). In addition, fluorescence in situ hybridization-based 1p/19q codeletion was performed in case 9. Next-generation sequencing (NGS) was performed for 4 patients in a CLIA-certified laboratory, using a targeted hot-spot panel of 50 genes (Ion AmpliSeq Cancer Hotspot Panel v2; ThermoFisher Scientific, Grand Island, NY) on an Ion Torrent platform (Ion PGM System; ThermoFisher Scientific). The 50 genes were ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, and VPL. The NGS reports were reviewed.
RESULTS
We identified 11 patients with glial and neuronal tumors of the ovary, including 4 ependymomas, 6 astrocytic tumors, and 1 neurocytoma ( Table 1 ). Patients' age ranged from 9 to 50 years (mean, 26 y; median, 24 y). The majority of patients presented with a pelvic mass with or without suspicious omental implant or peritoneal metastasis. As several cases were consult cases submitted by outside institutions, the data regarding tumor stage was not always available. Follow-up information was available for 8 patients (range: 4 to 59 mo; mean, 15 mo; median, 8.5 mo), of which 3 had no evidence of disease and 5 were alive with disease at last follow-up.
Ependymal Tumors
Four ependymal tumors were identified, including 2 low-grade ependymomas and 2 anaplastic ependymomas. Patients' age ranged from 29 to 50 years (mean, 37.5 y; median, 35.5 y). Three patients presented with pelvic masses, and 1 patient presented with an alleged broad ligament abscess (case 3). Grossly, case 2 was a 13.0 cm pink-tan mass; case 3 was a 7.0 cm pink-tan mass; case 4 was an 18.0 cm ovoid, ragged, pink mass (stage pT3c). Microscopically, the ependymomas exhibited round to oval nuclei with a fine "salt and pepper" chromatin pattern, perivascular pseudorosette formation, and rare true ependymal rosette formation. Two cases (cases 3 and 4) also showed areas of elevated mitotic activity, consistent with anaplastic ependymoma. In addition, vascular proliferation and necrosis were present in case 3 but not case 4. Multiple architectural patterns, including classical, papillary, and clear cell areas, were present ( Fig. 1 ). Importantly, all ependymomas involved both the ovary and the peritoneum, and none of them was associated with another ovarian neoplasm. The tumor cells were typically positive for GFAP, ER, PR, and EMA (perinuclear dotlike pattern) ( Table 2 ). The mutational status of 50 genes, including IDH1, IDH2, PIK3CA, and PTEN, was assessed by NGS in 1 low-grade ependymoma and 1 anaplastic ependymoma. No mutations in the covered coding regions of these genes were identified in either of the 2 cases.
The patients underwent either unilateral or bilateral salpingo-oophorectomy with or without hysterectomy. Three patients with adequate follow-up information were alive with disease at 4.5, 9, and 59 months, respectively (Table 1) .
Astrocytic Tumors
Six primary ovarian/peritoneal astrocytomas were identified (Table 1) , including 1 low-grade and 5 highgrade gliomas/astrocytomas. Patients' age ranged from 9 to 38 years (mean, 19.5 y; median, 18 y). All 6 patients also had coexistent ovarian germ cell tumors, including immature teratoma (n = 4), mature cystic teratoma (n = 1), and mixed germ cell tumor (n = 1). In 4 patients, astrocytomas arose from the ovary, and in the other 2 patients they arose from peritoneal implants (n = 1) or from gliomatosis peritonei (mature glial tissue in the peritoneal cavity) (n = 1). Of note, case 10 was also included in our recently published case series about gliomatosis peritonei. 10 Grossly, case 5 was a 7.5 cm multinodular mass, and multiple peritoneal nodules were also present; case 7 was a 16 cm solid and cystic mass with a smooth surface; case 8 was a 12-cm fleshly light-tan mass; case 9 was a 8.0 cm fungating pink and yellow-tan mass protruding from the luminal surface of the cystic wall of a 19.0 cm immature cystic teratoma. Of note, as astrocytoma usually arises from an ovarian germ cell tumor, it may not be possible to accurately measure the size of the astrocytoma, and the above measurement may also include the ovarian germ cell tumor component.
Microscopically, low-grade astrocytoma displayed moderately increased cellularity, low to moderate nuclear atypia, and very rare mitotic figures (Fig. 2) . In contrast, high-grade astrocytomas showed marked nuclear atypia and prominently elevated mitotic activity ( Fig. 3 ). Vascular proliferation and/or necrosis were identified in 4 tumors (cases 7 to 10), similar to CNS glioblastoma. Immunophenotyping results are shown in Table 2 . No IDH1-R132H mutations were identified in 4 of 4 astrocytomas (0%) by either IHC (n = 2) or NGS (n = 2). In the latter 2 cases, NGS failed to identify any mutations in the covered coding regions of the 50-gene panel, including IDH1, IDH2, PIK3CA, and PTEN.
Among 5 patients with operative notes available, all patients underwent unilateral salpingo-oophorectomy, or bilateral salpingo-oophorectomy, hysterectomy and omentectomy, and 1 patient had a previous history of left salpingo-oophorectomy for primary ovarian germ cell tumor and underwent cytoreductive surgery for the glioma (Table 1) . Among 4 patients with follow-up data, 
Neuronal Tumor
Only 1 neurocytoma was identified in our archival search. A 22-year-old woman had a previous history of ovarian mixed germ cell tumor with immature teratoma and yolk sac tumor components, and received 6 cycles of bleomycin, etoposide, cisplatin (BEP) chemotherapy. Eight months after the diagnosis of the original ovarian mixed germ cell tumor, a follow-up computed tomography scan of the abdomen showed multiple peritoneal nodules, and biopsy demonstrated a mature teratoma component. Moreover, a low-grade neurocytoma arising from the mature teratomatous elements was diagnosed on a diaphragmatic implant. Microscopically, the tumor measured 2.0 mm and formed a distinct nodule. There was no other intermixing teratoma component. The histologic features of the tumor included monotonously rounded nuclei with perinuclear cytoplasmic halos, and low mitotic activity (Fig. 4) . The tumor was adjacent to a cyst lined by ependyma-like cells, similar to central neurocytoma of the brain, which commonly arises adjacent to the lateral or third ventricle. The tumor cells strongly immunoexpressed synaptophysin, but not GFAP, S100 protein, IDH1-R132H, or SALL4. The quantitative Ki-67 proliferative index was 0.9% ( Table 2 ). The patient underwent unilateral salpingo-oophorectomy and omentectomy. Later, she was also diagnosed with growing teratoma syndrome. She was alive with disease 12 months after the diagnosis of neurocytoma (20 mo after the diagnosis of ovarian mixed germ cell tumor).
DISCUSSION
Primary neuroectodermal tumors of the ovary can be parsed into 3 groups: (1) differentiated tumors, resembling ependymoma or astrocytoma of the CNS; (2) primitive tumors, resembling embryonal tumor with multilayered rosettes (comprising the historical entities of medulloepithelioma, ependymoblastoma, and embryonal tumor with abundant neuropil and true rosettes), neuroblastoma, or medulloblastoma; (3) anaplastic tumors, resembling glioblastoma. 2 Our study represents one of the most comprehensive studies of this rare class of tumors, which has provided collective data on pathology, grading, molecular signature and therapeutic interventions. Our analysis has demonstrated several important differences between the primary CNS tumor cohort and the primary ovarian/peritoneum tumor cohort in terms of diagnostic terminology, biology, and clinical behavior. First, although the 2 groups share very similar morphologic features, the 4-tier WHO grading system (grades I to IV) for CNS gliomas has not been validated for extra-CNS gliomas. 11, 12 We thus choose to use a simple 2-tier system (low-grade, high-grade) for extra-CNS tumor grade stratification. Secondly, despite morphologic similarity, primary ovarian/peritoneum astrocytomas do not exhibit the canonical IDH mutations that define the majority of WHO grade II and III CNS diffuse astrocytomas. Finally, with respect to treatment and prognosis, diffuse gliomas of the CNS cannot be cured by surgical resection secondary to their widely infiltrative growth pattern (ie, infiltration along axons and dendrites), and ependymomas also can be difficult to totally extirpate without significant morbidity because of location in proximity to eloquent CNS centers; however, in sharp contrast, glial and neuronal tumors of the ovary can be extensively debulked and often totally resected through surgery, although it may not be possible to completely resect tumors with peritoneal dissemination. This feature is likely a major contributor to the difference in recurrence-free and overall survival between CNS patients and ovarian patients.
The origin of extra-CNS glial and neuronal tumors is not clear. One study observation is that, although astrocytomas and neurocytoma were often associated with ovarian germ cell tumors, there was no such association with ependymomas, although rare cases of ependymoma associated with ovarian teratoma have been previously reported by others. 13, 14 Earlier studies have reported primary ovarian ependymoma, 2,13,15-24 primary peritoneal ependymoma, 25, 26 and primary ependymoma of the broad ligament. [27] [28] [29] Extra-axial ependymomas may show different morphologic and immunophenotypic features from CNS ependymomas. Idowu et al 30 demonstrated that extra-axial ependymomas more frequently express cytokeratin markers, such as 34betaE12, CK18, CAM 5.2, and CK7, compared with CNS ependymomas. In addition, ovarian and peritoneal ependymomas are frequently positive for ER and PR; thus these tumors can potentially be treated with hormonal therapy. [15] [16] [17] 31 In contrast, astrocytic and neuronal tumors are often associated with ovarian germ cell tumors, but may also arise from metastatic tumor implants (ie, peritoneal or omental implant) or from gliomatosis peritonei, which is characterized by mature glial tissue in the peritoneal cavity, usually present in patients with ovarian immature teratoma. 10, 32, 33 From a diagnostic point of view, the differential diagnosis of glial and neuronal tumors of the ovary/peritoneum includes other primary ovarian neoplasms as well as metastatic neoplasms. Low-grade ependymoma may be misdiagnosed as low-grade endometrioid carcinoma or serous borderline tumor, and high-grade ependymoma may be misdiagnosed as high-grade serous carcinoma. In this setting, the presence of pseudorosettes and/or ependymal rosettes supports the diagnosis of ependymoma. In addition, IHC staining may be helpful in making a correct diagnosis. The combination of GFAP and other markers, including WT-1 and PAX8, may be helpful in problematic situations. High-grade serous carcinoma is typically positive for WT-1 and PAX8, whereas gliomas are usually strongly and diffusely positive for GFAP. Sex cord-stromal tumors, such as Sertoli-Leydig cell tumor or sclerosing stromal tumors, are also in the differential diagnosis; immunoexpression of inhibin and calretinin can be helpful as sex cord-stromal tumors usually show immunoreactivity for these 2 markers.
Although neurocytoma can be confused with oligodendroglioma (ie, both tumors demonstrate round nuclei with perinuclear halo), neurocytoma is typically negative for GFAP and positive for synaptophysin, whereas oligodendroglioma demonstrates the opposite immunophenotype. Interestingly, like their CNS counterparts, the neurocytoma we report and that reported by Hirschowitz and colleagues 34 both arose adjacent to an ependyma-lined cyst, mimicking the presence of a ventricle. A final diagnostic caveat is that mutational status will be incorporated into the definition and name of diffuse astrocytomas (eg, diffuse astrocytoma, IDH-mutant), and demonstration of IDH mutation and 1p/19q codeletion will define the highly clinically homogenous entity of "oligodendroglioma, IDH-mutant, and 1p/19q codeleted". 3, 36, 37 Moreover, molecular diversity has been demonstrated in diffuse gliomas that are otherwise indistinguishable by morphology. For example, pediatric diffuse gliomas of the CNS have a very different biology compared with adult diffuse gliomas, with Histone H3.3 mutations, not IDH mutations, serving as the driver mutations in a large subset of pediatric diffuse gliomas. [38] [39] [40] None of our interrogated ovarian astrocytic tumors exhibited IDH mutation ( Table 2 ). Because of the limited sample number, it is uncertain whether the lack of an IDH mutation signature is a characteristic of primary ovarian gliomas or, if so, what the molecular drivers are. Similarly, ependymomas of the CNS exhibit different molecular characteristics based on anatomic origin. Supratentorial ependymomas frequently carry C11orf95-RELA fusions that cause constitutive activation of the nuclear factor-kB signaling pathway. In contrast, posterior fossa ependymomas are divided into 2 distinct molecular and prognostic subgroups: group A-characterized by epigenetic changes, increased activation of several cancer signaling pathways, and a more aggressive prognosis, and group B-characterized by lack of epigenetic alterations, enriched in chromosomal number variations, and a good prognosis. [41] [42] [43] [44] [45] [46] In stark contrast, little is known about the genetic and epigenetic changes in extra-CNS ependymomas. NGS, performed on 2 ependymomas in our study, failed to detect mutations in the coding regions of a panel of 50 genes, including IDH1, IDH2, PIK3CA, and PTEN. Although these data strongly suggest that ovarian ependymomas may not carry mutations similar to those observed in CNS counterparts, such a conclusion awaits validation from a larger cohort.
In conclusion, our findings provide updated information on rare glial and neuronal tumors of the gynecologic tract (summarized in Table 3 ). Further molecular studies are needed to elucidate the molecular Surgical resection (ie, USO, TAH-BSO, or cytoreduction), followed by HIPEC, chemotherapy or radiation.* *Patients may receive chemotherapy for the treatment of ovarian germ cell tumors that are associated with gliomas.
HIPEC indicates hyperthermic intraperitoneal chemotherapy; TAH-BSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy; USO, unilateral salpingo-oophorectomy.
